Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
Open Access
- 7 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1591-1597
Abstract
Tightly-controlled dose reduction was possible during 1 year in psoriasis patients on adalimumab, etanercept or ustekinumab with low disease activity (CONDOR trial). Extended observation is needed ...Keywords
This publication has 9 references indexed in Scilit:
- Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With PsoriasisJAMA Dermatology, 2020
- Psoriasis: from Pathogenesis to Targeted TherapiesClinical Reviews in Allergy & Immunology, 2018
- Old and New Biological Therapies for PsoriasisInternational Journal of Molecular Sciences, 2017
- Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility StudyTherapeutic Drug Monitoring, 2017
- Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trialBMC Dermatology, 2017
- Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registryBritish Journal of Dermatology, 2017
- Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete ClearanceActa Dermato-Venereologica, 2017
- Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective studyJournal of the European Academy of Dermatology and Venereology, 2017
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007